New decision tool aims to reduce aggressive End-of-Life cancer care
NCT ID NCT04823377
First seen Nov 20, 2025 · Last updated Jun 19, 2026 · Updated 22 times
Summary
This study looks at whether a special decision-making tool can help doctors and patients with advanced non-small cell lung cancer decide when to stop cancer treatments. The goal is to reduce the number of patients receiving chemotherapy or other treatments in their last days of life, which can be harsh and offer little benefit. The study compares usual care to a period where the tool is used, involving 364 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP Ambroise Paré
Boulogne-Billancourt, 92100, France
-
AP-HP Bichat
Paris, 75018, France
-
AP-HP Cochin
Paris, 75014, France
-
AP-HP Tenon
Paris, 75970, France
-
CGFL
Dijon, 21000, France
-
CH Abbeville
Abbeville, 80142, France
-
CH Henri Duffaut Avignon
Avignon, 84000, France
-
CH Intercommunal de Créteil
Créteil, 94000, France
-
CH Saint-Malo
St-Malo, 35420, France
-
CH du Pays d'Aix
Aix-en-Provence, 13616, France
-
CHD Vendée
La Roche-sur-Yon, 85925, France
-
CHI de Compiègne-Noyon
Compiègne, 60200, France
-
CHR Metz-Thionville - Hôpital de Mercy
Ars-Laquenexy, France
-
CHRU Lille
Lille, 59000, France
-
CHU Amiens - Hôpital Sud
Amiens, 80054, France
-
CHU Angers
Angers, 49933, France
-
CHU Grenoble Alpes
Grenoble, 38043, France
-
CHU Sud Francilien
Corbeil-Essonnes, 91100, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Clinique Tessier
Valenciennes, 59300, France
-
Clinique des Cèdres
Cornebarrieu, 31700, France
-
Hôpital Foch
Suresnes, 92150, France
-
Institut Curie
Paris, 75005, France
-
Institut Curie
Saint-Cloud, 92210, France
-
Institut Sainte-Catherine
Avignon, 84918, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could provide a reliable way to help doctors and patients decide when to stop cancer treatments, potentially improving quality of life at the end of life.
What could go wrong
This is an observational-style study comparing two time periods, not a randomized trial, so results may be influenced by other changes over time. It does not test a new drug or treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.